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Purpose To evaluate randomly the role of hyperfractionated cyclophosphamide
(hyper-C) dose intensification in adults with newly diagnosed Philadelphia
chromosome-negative acute lymphoblastic leukemia treated with a pediatric-inspired
protocol and to determine the upper age limit for treatment tolerability in this
context. Patients and Methods A total of 787 evaluable patients (B/T lineage, 525 and
262, respectively; median age, 36.1 years) were randomly assigned to receive a
standard dose of cyclophosphamide or hyper-C during first induction and late
intensification. Compliance with chemotherapy was assessed by median doses
actually received during each treatment phase by patients potentially exposed to the
full planned doses. Results Overall complete remission (CR) rate was 91.9%. With a
median follow-up of 5.2 years, the 5-year rate of event-free survival (EFS) and overall
survival (OS) was 52.2% (95% CI, 48.5% to 55.7%) and 58.5% (95% CI, 54.8% to
61.9%), respectively. Randomization to the hyper-C arm did not increase the CR rate
or prolong EFS or OS. As a result of worse treatment tolerance, advanced age
continuously affected CR rate, EFS, and OS, with 55 years as the best age cutoff. At
5 years, EFS was 55.7% (95% CI, 51.8% to 59.4%) for patients younger than 55
years of age versus 25.8% (95% CI, 19.9% to 35.6%) in older patients (hazard ratio,
2.16; P < .001). Patients ≥ 55 years of age, in whom a lower compliance to the whole
planned chemotherapy was observed, benefited significantly from hyper-C, whereas
younger patients did not. Conclusion No significant benefit was associated with the
introduction of a hyper-C sequence into a frontline pediatric-like adult acute
lymphoblastic leukemia therapy. Overall, tolerability of an intensive pediatric-derived
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